Silencing of miR‑155 suppresses inflammatory responses in psoriasis through inflammasome NLRP3 regulation

Luo,Quan; Zeng,Jingxin; Li,Wei; Lin,Ling; Zhou,Xin; Tian,Xin; Liu,Weiyu; Zhang,Lidan; Zhang,Xibao

doi:10.3892/ijmm.2018.3677

Silencing of miR‑155 suppresses inflammatory responses in psoriasis through inflammasome NLRP3 regulation

Authors:
- Quan Luo
- Jingxin Zeng
- Wei Li
- Ling Lin
- Xin Zhou
- Xin Tian
- Weiyu Liu
- Lidan Zhang
- Xibao Zhang
View Affiliations

Affiliations: Department of Dermatology, Guangzhou Institute of Dermatology, Guangzhou, Guangdong 510095, P.R. China
Published online on: May 14, 2018 https://doi.org/10.3892/ijmm.2018.3677
Pages: 1086-1095

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Psoriasis is a dermatosis with the major clinical symptoms of scale, erythema and itching, and it has a long disease course. In addition, it is easily recurrent and refractory, greatly affecting the physical and mental health of patients. In the present study, it was hypothesized that the function of miR‑155 increases psoriasis‑induced inflammation and that its expression may be dependent on inflammasome activation. miR‑155 expression was examined by gene chip array and quantitative polymerase chain reaction analysis. miR‑155 expression levels were significantly increased in an in vivo model of psoriasis compared with normal tissues, as was the expression of NLR family pyrin domain containing 3 (NLRP3). In vitro, using keratinocyte‑induced HaCaT cells as a model for psoriasis, silencing of miR‑155 was confirmed to significantly decrease inflammation and NLRP3/caspase‑1 signaling. Activation of toll‑like receptor 4 (TLR4) enhanced the miR‑155‑induced inflammatory response in the in vitro keratinocyte model. Treatment with a TLR4 inhibitor or an NLRP3 inhibitor reversed the miR‑155‑mediated inflammation in the same cell system. The present study demonstrated that miR‑155 silencing suppressed psoriasis‑associated inflammatory responses through inflammasome NLRP3 regulation.

View Figures

View References

1	Reich K, Armstrong AW, Foley P, Song M, Wasfi Y, Randazzo B, Li S, Shen YK and Gordon KB: Efficacy and safety of gusel-kumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 76:418–431. 2017. View Article : Google Scholar : PubMed/NCBI
2	Balak DM, van Doorn MB, Arbeit RD, Rijneveld R, Klaassen E, Sullivan T, Brevard J, Thio HB, Prens EP, Burggraaf J and Rissmann R: IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasis. Clin Immunol. 174:63–72. 2017. View Article : Google Scholar
3	Hayashi M, Umezawa Y, Fukuchi O, Ito T, Saeki H and Nakagawa H: Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 41:974–980. 2014. View Article : Google Scholar : PubMed/NCBI
4	Zhao L, Chen X, Cai L, Zhang C, Wang Q, Jing S, Chen G, Li J, Zhang J and Fang Y: Randomized, double-blind, placebo-controlled, multiple-dose study of the safety, tolerability and pharmacokinetics of benvitimod, a candidate drug for the treatment of psoriasis. J Clin Pharm Ther. 39:418–423. 2014. View Article : Google Scholar : PubMed/NCBI
5	Yao DN, Lu CJ, Wen ZH, Yan YH, Xuan ML, Li XY, Li G, He ZH, Xie XL, Deng JW, et al: Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: Pilot study for a double-blind, randomized, placebo-controlled trial. Trials. 17:1402016. View Article : Google Scholar : PubMed/NCBI
6	Liu Q, Wu DH, Han L, Deng JW, Zhou L, He R, Lu CJ and Mi QS: Roles of microRNAs in psoriasis: Immunological functions and potential biomarkers. Exp Dermatol. 26:359–367. 2017. View Article : Google Scholar
7	Li Y, Su J, Li F, Chen X and Zhang G: miR-150 regulates human keratinocyte proliferation in hypoxic conditions through targeting HIF-1alpha and VEGFA: Implications for psoriasis treatment. PLoS One. 12:e01754592017. View Article : Google Scholar
8	Yu X, An J, Hua Y, Li Z, Yan N, Fan W and Su C: MicroRNA-194 regulates keratinocyte proliferation and differentiation by targeting Grainyhead-like 2 in psoriasis. Pathol Res Pract. 213:89–97. 2017. View Article : Google Scholar : PubMed/NCBI
9	Dupaul-Chicoine J, Arabzadeh A, Dagenais M, Douglas T, Champagne C, Morizot A, Rodrigue-Gervais IG, Breton V, Colpitts SL, Beauchemin N and Saleh M: The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity. 43:751–763. 2015. View Article : Google Scholar : PubMed/NCBI
10	Orlowski GM, Sharma S, Colbert JD, Bogyo M, Robertson SA, Kataoka H, Chan FK and Rock KL: Frontline science: Multiple cathepsins promote inflammasome-independent, particle-induced cell death during NLRP3-dependent IL-1β activation. J Leukoc Biol. 102:7–17. 2017. View Article : Google Scholar : PubMed/NCBI
11	Yuan C, Liu C, Wang T, He Y, Zhou Z, Dun Y, Zhao H, Ren D, Wang J, Zhang C and Yuan D: Chikusetsu saponin IVa ameliorates high fat diet-induced inflammation in adipose tissue of mice through inhibition of NLRP3 inflammasome activation and NF-kappaB signaling. Oncotarget. 8:31023–31040. 2017.PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
13	Maegdefessel L, Spin JM, Raaz U, Eken SM, Toh R, Azuma J, Adam M, Nakagami F, Heymann HM, Chernogubova E, et al: Erratum: miR-24 limits aortic vascular inflammation and murine abdominal aneurysm development. Nat Commun. 6:65062015. View Article : Google Scholar : PubMed/NCBI
14	Huang L, Cao J, Cao L, Gao L, Yang Y and Xu L: Puerarin induces cell apoptosis in human chondrosarcoma cell line SW1353 via inhibition of the PI3K/Akt signaling pathway. Oncol Lett. 14:5585–5590. 2017.PubMed/NCBI
15	Bala S, Csak T, Saha B, Zatsiorsky J, Kodys K, Catalano D, Satishchandran A and Szabo G: The pro-inflammatory effects of miR-155 promote liver fibrosis and alcohol-induced steatohepatitis. J Hepatol. 64:1378–1387. 2016. View Article : Google Scholar : PubMed/NCBI
16	Gottlieb A, Sullivan J, van Doorn M, Kubanov A, You R, Parneix A, Hugot S and Milutinovic M: Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 76:70–80. 2017. View Article : Google Scholar
17	Zhao M, Wang LT, Liang GP, Zhang P, Deng XJ, Tang Q, Zhai HY, Chang CC, Su YW and Lu QJ: Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin Immunol. 150:22–30. 2014. View Article : Google Scholar
18	Obora K, Onodera Y, Takehara T, Frampton J, Hasei J, Ozaki T, Teramura T and Fukuda K: Inflammation-induced miRNA-155 inhibits self-renewal of neural stem cells via suppression of CCAAT/enhancer binding protein β (C/EBPβ) expression. Sci Rep. 7:436042017. View Article : Google Scholar
19	Hoyt LR, Randall MJ, Ather JL, DePuccio DP, Landry CC, Qian X, Janssen-Heininger YM, van der Vliet A, Dixon AE, Amiel E and Poynter ME: Mitochondrial ROS induced by chronic ethanol exposure promote hyper-activation of the NLRP3 inflammasome. Redox Biol. 12:883–896. 2017. View Article : Google Scholar : PubMed/NCBI
20	Lv Z, Wei Z, Zhang Z, Li C, Shao Y, Zhang W, Zhao X, Li Y, Duan X and Xiong J: Characterization of NLRP3-like gene from Apostichopus japonicus provides new evidence on inflammation response in invertebrates. Fish Shellfish Immunol. 68:114–123. 2017. View Article : Google Scholar : PubMed/NCBI
21	Carlström M, Ekman AK, Petersson S, Söderkvist P and Enerbäck C: Genetic support for the role of the NLRP3 inflammasome in psoriasis susceptibility. Exp Dermatol. 21:932–937. 2012. View Article : Google Scholar : PubMed/NCBI
22	Irrera N, Vaccaro M, Bitto A, Pallio G, Pizzino G, Lentini M, Arcoraci V, Minutoli L, Scuruchi M, Cutroneo G, et al: BAY 11-7082 inhibits the NF-kappaB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis. Clin Sci (Lond). 131:487–498. 2017. View Article : Google Scholar
23	Artlett CM, Sassi-Gaha S, Hope JL, Feghali-Bostwick CA and Katsikis PD: mir-155 is overexpressed in systemic sclerosis fibroblasts and is required for NLRP3 inflammasome-mediated collagen synthesis during fibrosis. Arthritis Res Ther. 19:1442017. View Article : Google Scholar : PubMed/NCBI